Regulation FD Disclosure. On July 7, 2026, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company” or “SAB BIO”) issued a press release with Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, announcing that Breakthrough T1D, has awarded a grant to Michael J. Haller, M.D., Professor and Chief of Pediatric Endocrinology at the University of Florida in support of PRISE-hATG, a clinical study evaluating SAB-142 in patients with Stage 3 T1D who…

Entry into a Material Definitive Agreement. On April 28, 2026 (the “Effective Date”), SAB Biotherapeutics, Inc., a Delaware corporation (the “Company” or “SAB BIO”) entered into a Master Manufacturing Services Agreement (the “MSA”) with Emergent BioSolutions Canada Inc. (“Emergent”). Pursuant to the MSA, Emergent will perform clinical and commercial manufacturing and related services for the Company with respect to SAB-142 (the “Product”) at Emergent’s facility in Canada. The MSA commences on…

Regulation FD Disclosure. On April 22, 2026, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company” or “SAB BIO”) made available a presentation that includes additional information regarding the Company’s Phase 1 HUman anti-thymocyte biologic in first-in-MAN (HUMAN) clinical trial of SAB-142 (the “Presentation”). On April 22, 2026, the Company also issued a press release announcing the release of the data set forth in the Presentation (the “Release”). A copy of the Release is furnis…

Entry into a Material Definitive Agreement. On March 17, 2026, SAB Biotherapeutics, Inc. (the “Company” or “SAB”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, UBS Securities LLC, Citigroup Capital Markets, Inc. and Barclays Capital Inc. (collectively, the “Representatives”) as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten offering (the “Offering”) of (i) 19,324,677 shares (the “Firm…

Other Events. On March 10, 2026, the Company announced additional data from its Phase 1 HUman anti-thymocyte biologic in first-in-MAN (HUMAN) clinical trial of SAB-142. In the trial, the established T1D adult patient cohort demonstrated early signals of C-peptide preservation aligned with the anticipated mechanism of action of SAB-142. In the T1D cohort (n=6), SAB-142 treated study participants (n=4) showed no decrease in C-peptide levels at Day 120 compared to baseline. The placebo study par…

Director — David Zaccardelli, Rita Jain: Two new directors were appointed to the Board of Directors.

Other Events. Establishment of “At the Market Offering” Program On December 29, 2025, SAB Biotherapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “ Agreement ” ) with UBS Securities LLC (the “Agent”) with respect to an at-the-market offering program under which the Company may offer and sell from time to time through or to the Agent, as sales agent or principal, the Company’s common stock, par value $0.0001 per share, having an aggregate offering price of up to $75,000,000 (…

Director — Christine Hamilton and Jeffrey Spragens: The resignation of Christine Hamilton and Jeffrey Spragens as members of the Board of Directors was not due to any disagreement but still represents a genuine departure.

The filing pertains to an amendment of the equity incentive plan and does not involve any management changes.

Entry into a Material Definitive Agreement. Securities Purchase Agreement On July 21, 2025, SAB Biotherapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Offering ”), (i) 1,000,000 shares (the “ Shares ”) of the Company’s newly-designated Series B Convertible Preferred Stock, par value $0…

The Shares and Warrants are being sold and, upon exercise the securities underlying the Warrants and conversion of the Preferred Shares, will be issued without registration under the Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.

Other Events. Press Releases Related to Offering On July 21, 2025 the Company issued a press release announcing the entry into the Offering, a copy of which is attached hereto as Exhibit 99.1, and incorporated by reference herein. FDA On May 29th, 2025, the Company held a constructive Type B meeting with the U.S. Food and Drug Administration (the “ FDA ”). The meeting followed positive topline data from a Phase 1 single-ascending dose trial in healthy volunteers for SAB-142. The primary discu…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information included in

Entry into a Material Definitive Agreement. On January 30, 2025, SAB Biotherapeutics, Inc. (the “Company”) entered into a lease agreement, dated and effective February 1, 2025 (the “Sanford Lease Agreement”), with Sanford Health, a South Dakota non-profit corporation ( the “Landlord”). The Sanford Lease Agreement provides for a lease area of 21,014 from the Landlord to the Company, located at 2301 East 60th Street North, Sioux Falls, South Dakota 57104. Annual rent payable under the Sanford L…

Chief Financial Officer — Lucy To: Lucy To was appointed as the new Chief Financial Officer of SAB Biotherapeutics, Inc.

Chief Financial Officer — Michael King, Jr.: Mr. King resigned to pursue another opportunity.

Class I director — Dr. Jay S. Skyler: Dr. Jay S. Skyler was appointed as a Class I director of the Company.

Regulation FD Disclosure. On April 12, 2024, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company” or “SAB”), announced that it had completed dosing of cohort 3 for phase one trials of SAB-142 and has not observed any instances of serum sicknesses. The Company intends to issue a press release with a corporate update on or about April 16, 2024. Cautionary Note Regarding Forward-Looking Statements Certain statements made in this current report that are not historical facts are forwar…

Results of Operations and Financial Condition”, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be ex…

Entry into a Material Definitive Agreement. The disclosure set forth under

The filing describes new executive employment agreements for existing executives, which is a routine management matter.

Chief Executive Officer — Samuel J. Reich: Samuel J. Reich was promoted from Executive Chairman to Chief Executive Officer.

Entry into a Material Definitive Agreement. On January 26, 2024, SAB Biotherapeutics, Inc. (the “Company”) entered into a Controlled Equity Offering℠ Sales Agreement (the “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”). In accordance with the terms of the Agreement, pursuant to the Prospectus Supplement (as defined below), the Company may offer and sell from time to time through or to the Agent, as sales agent, the Company’s common stock, par value $0.0001 per share, having an aggrega…

of Form 8-K and will not be deemed to be filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act. The information contained in the Presentation is summary information that should be considered in the context of the Company’s filings with the Securit…

Material Modification to Rights of Security Holders. The disclosure set forth in